结核与肺部疾病杂志 ›› 2022, Vol. 3 ›› Issue (2): 118-124.doi: 10.19983/j.issn.2096-8493.20210166

• 论著 • 上一篇    下一篇

慢性阻塞性肺疾病急性加重期与慢性阻塞性肺疾病合并社区获得性肺炎的临床观察性分析

朱丹1, 陈燕2, 双庆翠1, 曾慧卉2()   

  1. 1邵阳学院附属第一医院呼吸与危重症医学科,邵阳 422000
    2中南大学湘雅二医院呼吸与危重症医学科,长沙 410011
  • 收稿日期:2022-01-01 出版日期:2022-06-30 发布日期:2022-04-18
  • 通信作者: 曾慧卉 E-mail:bonemarrow@csu.edu.cn
  • 基金资助:
    国家自然科学基金面上项目(82070049)

Clinical observation of patients with acute axcerbation of chronic obstructive pulmonary disease and patients with chronic obstructive pulmonary disease plus community-acquired pneumonia

ZHU Dan1, CHEN Yan2, SHUANG Qing-cui1, ZENG Hui-hui2()   

  1. 1Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Shaoyang University, Shaoyang 422000, China
    2Pulmonary and Critical Care Medicine, the Second Xiangya Hospital Central South University, Changsha 410011,China
  • Received:2022-01-01 Online:2022-06-30 Published:2022-04-18
  • Contact: ZENG Hui-hui E-mail:bonemarrow@csu.edu.cn
  • Supported by:
    General program of National Natural Science Foundation of China(82070049)

摘要: 目的 对比分析慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease, AECOPD)与慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)合并社区获得性肺炎(community-acquired pneumonia, CAP)患者的临床特点及差异。加强临床医生对AECOPD和COPD合并CAP的正确认识,提高诊疗水平,降低患者病死率。方法: 收集2017年1—6月于中南大学湘雅二医院及邵阳学院附属第一医院呼吸内科住院并明确诊断为COPD的患者,共101例,依据入组标准分为AECOPD组(42例)和COPD合并CAP组(59例),比较两组患者一般资料、临床症状、体征、炎症指标水平、营养状态水平、血气分析结果、肺功能检测结果、合并症、临床转归等方面的差异。结果: (1)COPD合并CAP组患者畏寒、发热、肺部啰音发生率分别为15.3%(9/59)、27.1%(19/59)、83.1%(49/59),高于AECOPD组患者[2.4%(1/42)、9.5%(4/42)、64.3%(27/42)],差异均有统计学意义(χ2值分别为4.558、3.448、11.053,P值分别为0.033、0.043、0.001)。(2)COPD合并CAP组患者C反应蛋白[M(Q1,Q3)]、降钙素原[M(Q1,Q3)]、血红细胞沉降率、B-型脑钠肽、动脉血二氧化碳分压分别为34.10(7.37,79.30)mg/L、0.17(0.09,0.25)ng/ml、32.00(14.00,53.00)mm/1h、430.00(140.00,2253.00)pg/ml、(51.26±16.15)mmHg (1mmHg=0.133kPa),高于AECOPD组患者[分别为5.62(2.94,13.95)mg/L、0.10(0.04,0.22)ng/ml、18.50(8.00,27.00)mm/1h、150.70(100.00,547.00)pg/ml、(45.71±9.94)mmHg],差异均有统计学意义(Z=-4.648,P=0.000;Z=-0.818,P=0.024;Z=-3.182,P=0.001;Z=-3.172,P=0.002;t=-3.621,P=0.035)。COPD合并CAP组患者第一秒用力呼气容积占预计值的百分比(FEV1%pred)和第一秒用力呼气容积占用力肺活量的百分比(FEV1/FVC%)分别为(45.00±14.70)%、(50.28±7.31)%,均明显低于AECOPD组[(52.02±15.42)%、(61.92±17.92)%],差异均有统计学意义(t值分别为5.124、2.726, P值分别为0.000、0.047)。(3)COPD合并CAP组心力衰竭发生率为28.8%(17/59)、机械通气使用比例为27.1%(16/59)、死亡率为6.8%(4/59),明显高于AECOPD组[11.9%(5/42)、9.5%(4/42)、2.4%(1/42)],差异均有统计学意义(χ2值分别为1.719、2.824、0.059,P值分别为0.042、0.003、0.027);COPD合并CAP组住院时间为(9.38±3.66)d,较AECOPD组[(6.28±2.04)d]患者住院时间更长,差异有统计学意义(t=-1.237,P=0.011)。结论: AECOPD与COPD合并CAP两组患者临床症状和体征存在差异,COPD合并CAP组住院患者较AECOPD患者的炎症反应更明显,病情更重,预后更差,在临床上需密切关注,及时治疗。

关键词: 肺疾病, 慢性阻塞性, 肺炎, 疾病特征

Abstract: Objective: To compare the clinical manifestations of acute axcerbation of chronic obstructive pulmonary disease (AECOPD) and chronic obstructive pulmonary disease (COPD) plus community-acquired pneumonia (CAP),thus to improve clinical diagnosis and treatment and reduce case fatality rate of them.Methods: We retrospectively collected 101 cases with definite COPD diagnosis hospitalized in Department of Respiratory in The Second Xiangya Hospital of Central South University and The First Hospital of ShaoYang University between January 2017 and June 2017. They were divided into AECOPD group and COPD-CAP group according to their medical histories and results of chest CT examination. The general information, clinical symptoms, signs, inflammation index, nutritional status, and results of blood gas analysis, pulmonary function test results, complications, and clinical outcomes were compared between the two groups.Results: (1) The incidence of chill, fever, lung rales in COPD-CAP group were 15.3% (9/59), 27.1% (19/59), 83.1% (49/59) respectively, which were significant higher than that of AECOPD group (2.4% (1/42), 9.5% (4/42), 64.3% (27/42), χ 2=4.558, 3.448, 11.053, P=0.033, 0.043, 0.037). (2)In the COPD-CAP group, median/mean of CRP, PCT, ESR, BNP and PaCO2 were 34.10 (7.37,79.30) mg/L, 0.17 (0.09,0.25) ng/ml, 32.00 (14.00,53.00)mm/1h、430.00 (140.00,2253.00)pg/ml, and (51.26±16.15)mmHg (1mmHg=0.133kPa) respectively, which were significant higher than that of the AECOPD group ((5.62 (2.94,13.95))mg/L, 0.10 (0.04,0.22)ng/ml, 18.50 (8.00,27.00)mm/1h、150.70 (100.00,547.00)pg/ml, and (45.71±9.94)mmHg, Z=-4.648,P=0.000;Z=-0.818,P=0.024;Z=-3.182,P=0.001;Z=-3.172,P=0.002;t=-3.621,P=0.035). The lung function of the two groups were all abnormally decreased,and the levels of FEV1%pred and FEV1/FVC% in the COPD-CAP group were (45.00±14.70)% and (50.28±7.31)%, which were lower than those in the AECOPD group ((52.02±15.42)%, (61.92±17.92)%), and the differences were statistically significant (t=5.124, 2.726, P=0.000, 0.047). (3) The occurrence rate of heart failure, mechanical ventilation, mortality in COPD-CAP group were 28.8% (17/59), 27.1% (16/59), and 6.8% (4/59),which were significantly higher than the AECOPD group (11.9% (5/42), 9.5% (4/42), 2.4% (1/42), χ2=1.719, 2.824, 0.059, P=0.042, 0.003, 0.027). The average length of stay in COPD-CAP group was (9.38±3.66) days, longer than AECOPD group ((6.28±2.04) days), the difference was statistically significant (t=-1.237,P=0.011).Conclusion: There were differences in clinical symptoms and signs between AECOPD group and COPD-CAP group. Compared with AECOPD group, hospitalized patients in COPD-CAP group got more obvious inflammatory reaction, more severe disease and worse prognosis, thus need to be closely monitored and timely treated in clinic practice.

Key words: Pulmonary disease, chronic obstructive, Pneumonia, Disease attributes

中图分类号: